(TheNewswire)
Toronto, Ontario / TheNewswire / February
27, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it will be exhibiting at the
American College of Cardiology’s 68th Annual Scientific Session & Expo to showcase its
next-generation VMS+ 3.0 system (http://2019.acccongress.com).
ACC’s Annual Scientific Session, taking place March 16 – 18, 2019 in New Orleans, is the global
marketplace for cardiovascular innovation with over 19,000 attendees from 120 countries. Ventripoint will be exhibiting in booth
#2426, performing live hands-on demonstrations of the VMS+ 3.0 system with a clinician.
“We are looking forward to performing live scanning of our next-generation VMS+ 3.0 system in our
booth. This will provide an opportunity for hands-on use by leading cardiologists from around the world,” notes Dave McPhedran,
Head of Global Sales at Ventripoint Diagnostics.
The VMS+ 3.0 system is designed to use Artificial Intelligence (AI) to provide a streamlined
approach for volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo images.
A new interactive guided workflow has been embedded in the VMS+ system to highlight view capture and point placement on each
view to increase efficiency and ease of use while performing imaging and analysis. The system uses a new
patent-pending position sensor, which allows the patient to re-position during the imaging portion of the exam. The compact and
portable system can be set-up within minutes.
The VMS+ 3.0 system is not commercially available for sale. For investigational use only.
In other news, on February 5, 2019 the Board of Directors granted a total of 625,000 common share stock options
at an exercise price of $0.16 per share. Three Officers of the Company were granted a total of 175,000 options and four independent
directors were granted a total of 200,000 options, all of which have a maturity date of five years from the date of issuance, and
vest over either three years or one year, respectively. The remaining options were granted to employees and consultants.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The
Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to
improve cardiac care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2019 TheNewswire - All rights reserved.